\-\ Texto\\:\\ \ \(0\)\
\-\ cbc\\ shows\\ an\\ mcv\\ of\\ 115\\.\ \(0\)\
\-\ parenteral\\ b12\\ injection\\ is\\ the\\ traditional\\ therapy\\ \\-\\ im\\ or\\ subq\\.\\ \\ however\\,\\ recent\\ reports\\ have\\ shown\\ both\\ safety\\ and\\ efficacy\\ for\\ high\\ dose\\ oral\\ b12\\ of\\ 1\\ milligram\\ \\(1\\,000\\ \\Â\\µg\\)\\ of\\ vitamin\\ b12\\ consumed\\ daily\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.cdc\\.gov\\/ncbddd\\/b12\\/patients\\.html\ \(1\)\
\-\ increased\\ t2\\ signal\\ in\\ the\\ dorsal\\ columns\\ of\\ the\\ spinal\\ cord\\ \\(bilateral\\)\ \(0\)\
\-\ vitamin\\ b12\\ deficiency\\ \\(sub\\-acute\\ combined\\ degeneration\\)\ \(0\)\
\-\ subacute\\ combined\\ degeneration\ \(1\)\
\-\ lightning\\ strike\\ to\\ upper\\ body\ \(1\)\
\-\ no2\\ toxicity\ \(0\)\
\-\ hiv\\ myelopathy\ \(0\)\
\-\ spinal\\ dural\\ av\\ fistula\ \(0\)\
\-\ transverse\\ myelitis\ \(14\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ radiation\ \(402\)\
\-\ leptomeningeal\\ carcinomatosis\ \(1\)\
\-\ compressive\\ myelopathy\ \(1\)\
\-\ 60\\ y\\/o\\ man\\ with\\ rapid\\ onset\\ of\\ gait\\ ataxia\\ and\\ loss\\ of\\ proprioception\\.\\ he\\ had\\ shoulder\\ surgery\\ 2\\ weeks\\ prior\\ and\\ received\\ nitrous\\ oxide\\ anesthesia\\.\ \(0\)\
\-\ this\\ patient\\ had\\ nitrous\\ oxide\\ anesthesia\\ for\\ shoulder\\ surgery\\ a\\ few\\ months\\ prior\\ to\\ admission\\.\\ he\\ also\\ had\\ egd\\ \\(esophago\\-gastro\\-duodenoscopy\\)\\ that\\ showed\\ an\\ atrophic\\ gastritis\\.\\ on\\ his\\ cbc\\ there\\ was\\ a\\ macrocytosis\\ with\\ an\\ mcv\\ of\\ 115\\ \\(normal\\ 80\\-100\\)\\ \\.\\ his\\ serum\\ b12\\ level\\ was\\ found\\ to\\ be\\ 42\\,\\ with\\ a\\ normal\\ range\\ of\\ 190\\-900\\.\\ he\\ was\\ started\\ on\\ vitamin\\ b12\\ injections\\ and\\ his\\ neurologic\\ status\\ began\\ to\\ gradually\\ improve\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ b12\\:\\ 0\\.5688278093782062\ \(0\)\
\-\ vitamin\\:\\ 0\\.19157946589949018\ \(0\)\
\-\ nitrous\\:\\ 0\\.185958639197702\ \(0\)\
\-\ oxide\\:\\ 0\\.17982159296355635\ \(0\)\
\-\ myelopathy\\:\\ 0\\.15024813878262475\ \(0\)\
\-\ 115\\:\\ 0\\.14444704811916034\ \(0\)\
\-\ mcv\\:\\ 0\\.14250637102345926\ \(0\)\
\-\ anesthesia\\:\\ 0\\.13989092782714962\ \(0\)\
\-\ combined\\:\\ 0\\.12067468460169314\ \(0\)\
\-\ degeneration\\:\\ 0\\.11316606383907375\ \(0\)\
\-\ his\\:\\ 0\\.11070280306218191\ \(0\)\
\-\ he\\:\\ 0\\.1080902683400243\ \(0\)\
\-\ cbc\\:\\ 0\\.1015314809021782\ \(0\)\
\-\ subq\\:\\ 0\\.09730416002701107\ \(0\)\
\-\ milligram\\:\\ 0\\.09730416002701107\ \(0\)\
\-\ \\Â\\µg\\:\\ 0\\.09730416002701107\ \(0\)\
\-\ macrocytosis\\:\\ 0\\.09730416002701107\ \(0\)\
\-\ of\\:\\ 0\\.09525654160045338\ \(0\)\
\-\ shoulder\\:\\ 0\\.09452902554557718\ \(0\)\
\-\ consumed\\:\\ 0\\.092979319598851\ \(0\)\
\-\ lightning\\:\\ 0\\.092979319598851\ \(0\)\
\-\ no2\\:\\ 0\\.092979319598851\ \(0\)\
\-\ had\\:\\ 0\\.09094542309369681\ \(0\)\
\-\ strike\\:\\ 0\\.08753066504085168\ \(0\)\
\-\ spinal\\:\\ 0\\.08640773672594901\ \(0\)\
\-\ columns\\:\\ 0\\.08251743293654527\ \(0\)\
\-\ im\\:\\ 0\\.08126111562545803\ \(0\)\
\-\ parenteral\\:\\ 0\\.08013730149561878\ \(0\)\
\-\ safety\\:\\ 0\\.0781925925083852\ \(0\)\
\-\ proprioception\\:\\ 0\\.07733882745880771\ \(0\)\
\-\ traditional\\:\\ 0\\.07654836448774023\ \(0\)\
\-\ gastritis\\:\\ 0\\.07654836448774023\ \(0\)\
\-\ efficacy\\:\\ 0\\.07386775208022513\ \(0\)\
\-\ toxicity\\:\\ 0\\.07386775208022513\ \(0\)\
\-\ myelitis\\:\\ 0\\.07329105115155833\ \(0\)\
\-\ egd\\:\\ 0\\.07172732441055205\ \(0\)\
\-\ atrophic\\:\\ 0\\.07172732441055205\ \(0\)\
\-\ an\\:\\ 0\\.06980059842170586\ \(0\)\
\-\ prior\\:\\ 0\\.06808560017567011\ \(0\)\
\-\ av\\:\\ 0\\.06773070584607947\ \(0\)\
\-\ injections\\:\\ 0\\.06708406126401673\ \(0\)\
\-\ compressive\\:\\ 0\\.06618214096821207\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.06589768760632543\ \(0\)\
\-\ surgery\\:\\ 0\\.06542552894300026\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.06433396086531915\ \(0\)\
\-\ was\\:\\ 0\\.0636150971421687\ \(0\)\
\-\ gradually\\:\\ 0\\.0634058654179194\ \(0\)\
\-\ to\\:\\ 0\\.06084437125098545\ \(0\)\
\-\ hiv\\:\\ 0\\.060171968927415415\ \(0\)\
\-\ deficiency\\:\\ 0\\.05953498153833666\ \(0\)\
\-\ ataxia\\:\\ 0\\.05908102498975934\ \(0\)\
\-\ improve\\:\\ 0\\.05908102498975934\ \(0\)\
\-\ daily\\:\\ 0\\.05769383034437829\ \(0\)\
\-\ subacute\\:\\ 0\\.05694059732008624\ \(0\)\
\-\ dose\\:\\ 0\\.05682007209509103\ \(0\)\
\-\ rapid\\:\\ 0\\.056583031919536876\ \(0\)\
\-\ began\\:\\ 0\\.056583031919536876\ \(0\)\
\-\ dorsal\\:\\ 0\\.056124192620166026\ \(0\)\
\-\ fistula\\:\\ 0\\.05495556174824966\ \(0\)\
\-\ serum\\:\\ 0\\.054560465879159734\ \(0\)\
\-\ 42\\:\\ 0\\.05408632698033733\ \(0\)\
\-\ dural\\:\\ 0\\.05399397688896773\ \(0\)\
\-\ injection\\:\\ 0\\.052943978755613685\ \(0\)\
\-\ received\\:\\ 0\\.052943978755613685\ \(0\)\
\-\ gait\\:\\ 0\\.05269687035447443\ \(0\)\
\-\ few\\:\\ 0\\.051613845448041235\ \(0\)\
\-\ started\\:\\ 0\\.0512522389908335\ \(0\)\
\-\ admission\\:\\ 0\\.0507657404510891\ \(0\)\
\-\ and\\:\\ 0\\.05029137276594387\ \(0\)\
\-\ normal\\:\\ 0\\.049685087992927035\ \(0\)\
\-\ oral\\:\\ 0\\.04873082907493313\ \(0\)\
\-\ neurologic\\:\\ 0\\.0486191383274536\ \(0\)\
\-\ reports\\:\\ 0\\.04731355363583148\ \(0\)\
\-\ range\\:\\ 0\\.047215696353840174\ \(0\)\
\-\ shown\\:\\ 0\\.04716710233392683\ \(0\)\
\-\ transverse\\:\\ 0\\.046880097514326285\ \(0\)\
\-\ 60\\:\\ 0\\.04550903087341239\ \(0\)\
\-\ cord\\:\\ 0\\.04510186812169807\ \(0\)\
\-\ http\\:\\ 0\\.04498268957543986\ \(0\)\
\-\ sclerosis\\:\\ 0\\.043338461554794885\ \(0\)\
\-\ status\\:\\ 0\\.04246127965953949\ \(0\)\
\-\ recent\\:\\ 0\\.0411980338851218\ \(0\)\
\-\ showed\\:\\ 0\\.040526971812985986\ \(0\)\
\-\ radiation\\:\\ 0\\.040320851989866395\ \(0\)\
\-\ body\\:\\ 0\\.04004378786895571\ \(0\)\
\-\ found\\:\\ 0\\.03936939099331542\ \(0\)\
\-\ onset\\:\\ 0\\.039070206770868254\ \(0\)\
\-\ loss\\:\\ 0\\.03706891213940126\ \(0\)\
\-\ for\\:\\ 0\\.03688321372908573\ \(0\)\
\-\ level\\:\\ 0\\.036753809691534446\ \(0\)\
\-\ on\\:\\ 0\\.03675237776028104\ \(0\)\
\-\ weeks\\:\\ 0\\.0364655119003677\ \(0\)\
\-\ the\\:\\ 0\\.03642225639777394\ \(0\)\
\-\ however\\:\\ 0\\.036013036894805776\ \(0\)\
\-\ with\\:\\ 0\\.035742546510510474\ \(0\)\
\-\ shows\\:\\ 0\\.03571066288199299\ \(0\)\
\-\ months\\:\\ 0\\.03541662490498247\ \(0\)\
\-\ t2\\:\\ 0\\.035005721367115744\ \(0\)\
\-\ therapy\\:\\ 0\\.03495931214703157\ \(0\)\
\-\ high\\:\\ 0\\.0345802257349138\ \(0\)\
\-\ signal\\:\\ 0\\.03449121518563979\ \(0\)\
\-\ both\\:\\ 0\\.033930076513778225\ \(0\)\
\-\ increased\\:\\ 0\\.03290200129051808\ \(0\)\
\-\ bilateral\\:\\ 0\\.032700267259851167\ \(0\)\
\-\ upper\\:\\ 0\\.032514545175071366\ \(0\)\
\-\ man\\:\\ 0\\.03221201868754023\ \(0\)\
\-\ have\\:\\ 0\\.030395339671624454\ \(0\)\
\-\ multiple\\:\\ 0\\.02976054003128113\ \(0\)\
\-\ also\\:\\ 0\\.028619673349572876\ \(0\)\
\-\ that\\:\\ 0\\.026404382828867777\ \(0\)\
\-\ be\\:\\ 0\\.02468232292499607\ \(0\)\
\-\ there\\:\\ 0\\.024209976714744497\ \(0\)\
\-\ or\\:\\ 0\\.021166839652309786\ \(0\)\
\-\ this\\:\\ 0\\.02090738595279627\ \(0\)\
\-\ patient\\:\\ 0\\.01978977500366234\ \(0\)\
\-\ is\\:\\ 0\\.016662775366972287\ \(0\)\
\-\ in\\:\\ 0\\.01513622384542528\ \(0\)\
